Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
2024年10月18日 - 7:50PM
Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG)
(“
Bright Minds” or the “
Company”)
is pleased to announce a non-brokered private placement of common
shares in the capital of the Company (“
Shares”) at
a price of USD$21.70 per Share (the “
Share
Offering”). In addition to the Shares issued under the
Share Offering, the Company reserves the right to issue pre-funded
warrants of the Company (“
PFWs”) at USD$21.699 per
PFW (the “
PFW Offering”, together with the Share
Offering, the “
Offering”). The aggregate gross
proceeds of the Share Offering and the PFW Offering, on a combined
basis, is for up to USD$35,000,000. The Company, in its sole
discretion, may determine the number of PFWs issued pursuant to the
PFW Offering and the number of Shares issued pursuant to the Share
Offering.
Each PFW is exercisable into one Share (each, a
“PFW Share”) at an exercise price of $0.001 per
PFW Share on the date that is the earlier of (a) the date the
holder thereof elects to exercise the PFWs and pays the exercise
price therefor, and (b) 5 years from the date of closing (the
“Closing Date”).
The Company intends to use the aggregate gross
proceeds from the Offering for research and development related to
its drug development programs, and general working capital. Each of
the Share Offering and the PFW Offering may close on one or more
dates as the Company may determine.
The Company may pay a finder’s fee in connection
with the Offering to eligible arm’s length finders in accordance
with the policies of the Canadian Securities Exchange.
All securities issued in connection with the
Offering will be subject to a statutory hold period of four months
and one day following the Closing Date in accordance with
applicable Canadian securities laws.
The Shares, the PFWs and PFW Shares
(collectively, the “Securities”) have not been
registered under the U.S. Securities Act of 1933, as amended (the
“U.S. Securities Act”) or any state securities
laws. Accordingly, the Securities of the Company may not be offered
or sold in the United States or to, or for the account or benefit
of, “U.S. persons” (as defined in Regulation S under the U.S.
Securities Act) absent registration or an applicable exemption from
the registration requirements of the U.S. Securities Act and
applicable state securities laws. Any Securities offered and sold
in the United States shall be issued as “restricted securities” as
defined in Rule 144(a)(3) under the U.S. Securities Act. This press
release shall not constitute an offer to sell or the solicitation
of any offer to buy, nor shall there be any sale of the Securities
in any jurisdiction in which such offer, solicitation or sale would
be unlawful.
The Company intends to use its reasonable
commercial efforts to file a registration statement with the
Securities and Exchange Commission after closing to register the
Shares and any PFW Shares underlying PFWs for resale under the U.S.
Securities Act.
About Bright Minds
Bright Minds Biosciences is a biotechnology
company developing innovative treatments for patients with
neurological and psychiatric disorders. Our pipeline includes novel
compounds targeting key receptors in the brain to address
conditions with high unmet medical need, including epilepsy,
depression, and other CNS disorders. Bright Minds is focused on
delivering breakthrough therapies that can transform patients'
lives. Bright Minds Biosciences has developed a unique platform of
highly selective serotonergic agonists exhibiting selectivity at
different serotonergic receptors. This has provided a rich
portfolio of NCE programs within neurology and psychiatry.
Company Contact:Alex
Vasilkevich Chief Operating Officer Bright Minds Biosciences Inc.
T: (414)7316422 E: alex@brightmindsbio.com
www.brightmindsbio.com
Investor Relations:Lisa WilsonT:
917-543-9932E: lwilson@insitecony.com
The Canadian Securities Exchange has neither
approved nor disapproved the information contained herein and does
not accept responsibility for the adequacy or accuracy of this news
release.
This news release contains “forward-looking
information”. Often, but not always, forward-looking statements can
be identified by the use of words such as “plans”, “expects”, “is
expected”, “budget”, “scheduled”, “estimates”, “forecasts”,
“intends”, “anticipates”, or “believes” or variations (including
negative variations) of such words and phrases, or state that
certain actions, events or results “may”, “could”, “would”, “might”
or “will” be taken, occur or be achieved. Forward-looking
statements in this news release include the completion of the
Offering as well as the use of proceeds for the Offering. A variety
of factors, including known and unknown risks, many of which are
beyond our control, could cause actual results to differ materially
from the forward-looking information in this news release. These
factors include the company’s financial position and operational
runway, regulatory risk to operating in the pharmaceutical
industry, and inaccuracies related to the assumption made by
management relating to general availability of resources required
to operate the studies noted in this news release. Additional risk
factors can also be found in the Company’s public filings under the
Company’s SEDAR+ profile at www.sedarplus.ca. Forward-looking
statements contained herein are made as of the date of this news
release and the Company disclaims any obligation to update any
forward-looking statements, whether as a result of new information,
future events or results or otherwise. There can be no assurance
that forward-looking statements will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in such statements. The Company undertakes no
obligation to update forward-looking statements if circumstances,
management’s estimates or opinions should change, except as
required by securities legislation. Accordingly, the reader is
cautioned not to place undue reliance on forward-looking
statements.
Bright Minds Biosciences (NASDAQ:DRUG)
過去 株価チャート
から 11 2024 まで 12 2024
Bright Minds Biosciences (NASDAQ:DRUG)
過去 株価チャート
から 12 2023 まで 12 2024